Loading...
Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series
The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Acquired drug resistance and drug toxicity are key challenges when using these drugs. We investigated whether vemurafenib toxicit...
Na minha lista:
Main Authors: | , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
SAGE Publications
2014
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4206651/ https://ncbi.nlm.nih.gov/pubmed/25364391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014548187 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|